Last reviewed · How we verify
Nimotop
Nimotop is a Small molecule drug developed by Rijnstate Hospital. It is currently in Phase 2 development. Also known as: RVG 12060.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Nimotop |
|---|---|
| Also known as | RVG 12060 |
| Sponsor | Rijnstate Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pilot Study: Effects of Nimodipine on Alcohol Drinking (PHASE2)
- Nimodipine Variability in SAH
- Effect of Extracorporeal Shock Wave Therapy (ESWT) and Phonophoresis Treatment in Patients With Lateral Epicondylitis (NA)
- Delayed Cerebral Infarction Beyond Endoluminal Spasmolysis and Induced Hypertension
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Effectiveness of Calcium Channel Blockade for OP and Carbamate Pesticide Poisoning (PHASE3)
- Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage (PHASE3)
- Evaluation of Extracorporeal Shockwave Therapy and Complex Decongestive Therapy Results in Patients With Lipedema (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nimotop CI brief — competitive landscape report
- Nimotop updates RSS · CI watch RSS
- Rijnstate Hospital portfolio CI
Frequently asked questions about Nimotop
What is Nimotop?
Who makes Nimotop?
Is Nimotop also known as anything else?
What development phase is Nimotop in?
Related
- Manufacturer: Rijnstate Hospital — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: RVG 12060
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing